Where does Edgewise Therapeutics, Inc.'s cash flow data come from?

Every line is extracted from Edgewise Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$176.01M-4.9%	-$167.8M-6.7%	-$157.24M-4.3%	-$150.7M-3.2%	-$146.09M-9.2%
Depreciation and amortization	$2.06M+1.2%	$2.04M-2.5%	$2.09M0.0%	$2.09M0.0%	$2.09M+2.0%
Stock-based compensation	$34.41M-1.0%	$34.75M+6.6%	$32.61M+3.8%	$31.41M+8.7%	$28.9M+16.9%
Net cash from operating activities	-$148.49M-3.3%	-$143.82M-8.8%	-$132.18M-5.9%	-$124.78M-5.5%	-$118.3M-8.5%
Capital expenditures	$472K+84.4%	$256K-44.0%	$457K-47.6%	$872K-17.7%	$1.06M-19.3%
Net cash from investing activities	——	——	——	——	——
Net cash from financing activities	$206.04M+5.1%	$196.09M+0.6%	$195.01M-0.9%	$196.68M+1,791%	$10.4M-95.8%
Net increase (decrease) in cash	——	——	——	——	——
Free cash flow	-$148.97M-3.4%	-$144.07M-8.6%	-$132.64M-5.6%	-$125.65M-5.3%	-$119.36M-8.2%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Edgewise Therapeutics, Inc.'s cash flow data come from?: Every line is extracted from Edgewise Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.